SCHEMBL15047723

SCHEMBL15047723

Cc1cnc(S(C)(=O)=O)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 2/20 0.45
NOS2 P35228 2/20 0.45
NOS1 P29475 1/20 0.45
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
CCR1 P32246 1/20 0.35
CCR5 P51681 1/20 0.35
CCR8 P51685 1/20 0.35
KMT2A Q03164 2/20 0.35
PTGS2 P35354 3/20 0.35
PTGS1 P23219 1/20 0.35
SMO Q99835 3/20 0.35
MEN1 O00255 1/20 0.33
APLNR P35414 2/20 0.32
RAPGEF4 Q8WZA2 1/20 0.32
CYP1A2 P05177 1/20 0.32
CA1 P00915 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27263643 0.83 NOS3 (0.42) NOS3NOS2NOS1KDM4EALDH1A1
SCHEMBL2172509 0.81 S100A9 (0.36) KDM4EALDH1A1LMNAPTGS2PTGS1
SCHEMBL30540038 0.81 NOS3 (0.43) NOS3NOS2NOS1KDM4EALDH1A1
SCHEMBL15109982 0.81 ENPP2 (0.35) KDM4EALDH1A1GAAMAPTPTGS2
SCHEMBL31579235 0.81 NOS3 (0.43) NOS3NOS2NOS1KDM4EALDH1A1
SCHEMBL25364838 0.81 NOS3 (0.43) NOS3NOS2NOS1KDM4EALDH1A1
SCHEMBL7511857 0.79 LMNA (0.41) LMNAKMT2APTGS2PTGS1SMO
SCHEMBL9989119 0.79 KMT2A (0.37) KDM4EALDH1A1LMNAKMT2APTGS2
SCHEMBL12186141 0.76 GLP1R (0.37) ALDH1A1LMNAPTGS2PTGS1
SCHEMBL22561920 0.75 KMT2A (0.35) KDM4EALDH1A1LMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024138211-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. (US) 2024-06-27 WO disclosed
US-8754226-B2 Piperidinyl-substituted lactams as GPR119 modulators ARRAY BIOPHARMA INC. (US) 2014-06-17 US disclosed
WO-2013093849-A1 DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRIDO-OXAZINE DERIVATIVES NOVARTIS AG (CH) 2013-06-27 WO disclosed
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS GPR119, GPR139, GPR39 NOS3 1860/4885NOS2 1229/4885NOS1 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.